ASRM 2016-Wednesday, October 19

October 19, 2016 – 7:00am

Poster Presentation P-468

Ndeye-Aicha Gueye, MD

Versican Proteolysis in the Pathogenesis of Uterine Leiomyoma

Full text is at http://www.fertstert.org/article/S0015-0282(16)62221-5/fulltext?rss=yes

This laboratory study was designed to investigate ADAMTS-mediated cleavage of versican during human myometrium and leiomyoma ECM remodeling.

October 19, 2016 – 7:00am

Poster Presentation P-447

Alexander Kotlyar MD

DMARD Usage Decreases Opioid Usage in Endometriosis Patients.

Full text is at http://www.fertstert.org/article/S0015-0282(16)62199-4/fulltext?rss=yes

This retrospective study was designed to more thoroughly investigate how the inhibitory effects of disease modifying anti-rheumatic drugs (DMARDs) affect the course of endometriosis. It seeks to determine if DMARDs can lead to decreased use of hormonal treatments, ablative surgery, and adjunct therapies.

October 19, 2016 – 7:00am

Poster Presentation P-542 Dr. Flyckt requested we not do this one, she indicated it wasn’t very good.

Alexander Kotlyar MD, Rebecca Flyckt, MD, and R. Baird, MD

Analysis of VEGF and FGF in Human Serum and Follicular Fluid as Markers of IVF Cycle Response

Full text is at http://www.fertstert.org/article/S0015-0282(16)62294-X/fulltext?rss=yes

This prospective study was designed to determine if serum and/or follicular fluid VEGF and FGF across an IVF cycle are associated with IVF cycle response. During stimulation, increasing FGF values showed some predictive value for HCG positivity and clinical pregnancy.

October 19, 2016 – 7:00am

Poster Presentation P-454

Thanh Ha Luu, MD

Cost Value of Laparoscopic vs Robotic Surgery for Endometriosis

Full text is at http://www.fertstert.org/article/S0015-0282(16)62206-9/fulltext

This study was designed to identify drivers of costs between robotic and conventional laparoscopy for the treatment of endometriosis. The primary driver of cost was surgical costs, with a significant difference between the robotic and laparoscopy.

October 19, 2016 – 11:15am

Oral Presentation O-235

Linda D. Bradley, MD

Results of the Asteroid (Assess Safety and Efficacy of Vilaprisan in Patients with Uterine Fibroids) 1 Study: A Phase, Placebo-Controlled Dose Finding Study

Full text is at http://www.fertstert.org/article/S0015-0282(16)61691-6/fulltext

Selective progesterone receptor modulators (SPRMs) in women with uterine fibroids (UFs) reduce heavy menstrual bleeding (HMB) and tumor size. We report the results of ASTEROID1, examining the efficacy and safety of the novel SPRM, vilaprisan, in women with UFs.

October 19, 2016 – 1:15pm-2:15pm

Interactive Session RS ED

Tommaso Falcone, MD

Controversies in the Management of Advanced Endometriosis and Endometrioma

This interactive session involves case presentations by physicians from three different institutions.